China's volume-based procurement (VBP) scheme is already in its fourth round for medical devices – and 10th round for pharma – and companies affected by these price-cutting schemes should be preparing their growth strategies locally.
That was the advice of Hua Su, life science and healthcare practice leader and partner at Ernest & Young Parthenon,...